[HTML][HTML] PARP inhibitors in the management of breast cancer: current data and future prospects

L Livraghi, JE Garber - BMC medicine, 2015 - Springer
L Livraghi, JE Garber
BMC medicine, 2015Springer
Abstract Poly (ADP-ribose) polymerases (PARP) are enzymes involved in DNA-damage
repair. Inhibition of PARPs is a promising strategy for targeting cancers with defective DNA-
damage repair, including BRCA1 and BRCA2 mutation-associated breast and ovarian
cancers. Several PARP inhibitors are currently in trials in the adjuvant, neoadjuvant, and
metastatic settings for the treatment of ovarian, BRCA-mutated breast, and other cancers.
We herein review the development of PARP inhibitors and the basis for the excitement …
Abstract
Poly(ADP-ribose) polymerases (PARP) are enzymes involved in DNA-damage repair. Inhibition of PARPs is a promising strategy for targeting cancers with defective DNA-damage repair, including BRCA1 and BRCA2 mutation-associated breast and ovarian cancers. Several PARP inhibitors are currently in trials in the adjuvant, neoadjuvant, and metastatic settings for the treatment of ovarian, BRCA-mutated breast, and other cancers. We herein review the development of PARP inhibitors and the basis for the excitement surrounding these agents, their use as single agents and in combinations, as well as their toxicities, mechanisms of acquired resistance, and companion diagnostics.
Springer